Daily Brief ECM: IPO Databook: Junlebao Dairy Group (HK) – Aug 2026 and more

• Junlebao Dairy Group Co., Ltd. is a reputable Chinese dairy company with over 30 years of experience. It ranked No. 3 in China’s dairy market in 2025 with a 4.3%.
• The company operated 33 dairy farms and 20 dairy production facilities across China as of June 30, 2026, cooperating with approximately 5,200 distributors.
• The company reported a net loss attributable to owners of (21,442) in 2023 and net current liabilities of 5,276,220 as of December 31, 2024.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Panacro (Hangzhou) Pharmaceutical Consulting Co., Ltd. is a clinical CRO based in Hangzhou, China, advancing clinical research through digital transformation. It provides clinical trial technical services to accelerate drug development.
• Proprietary digital infrastructure integrates CTMS, eTMF, and CTFS across the full project lifecycle. The company reported a gross profit margin of 38.9% in 2025.
• Net cash generated from operating activities was RMB46,583 thousand for the six months ended June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Medcaptain Medical Technology is a global medical device provider with a product portfolio across life support, minimally invasive intervention, and in vitro diagnostics, serving over 140 countries and regions.
• The company ranked first in China’s infusion workstation market from 2018 to 2025, reaching over 6,000 hospitals in China and 140 countries globally.
• FY2025 revenue was RMB1,619,152 thousand, and gross profit was RMB869,660 thousand. The company reported a net loss of RMB96,617 thousand in FY2024.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• NexGel, Inc. manufactures high water content hydrogels for various applications, serving as a contract manufacturer and marketing branded consumer products, recently acquiring Celularity Inc.’s BioNx portfolio.
• NexGel manufactures high water content hydrogels, specializing in custom gels using proprietary technologies. The company acquired Celularity Inc.’s BioNx portfolio on April 17, 2026, and operates two segments.
• NexGel reported a net loss of $4.5 million and used $2.7 million cash in operations for the six months ended June 30, 2026, with substantial doubt about its ability to.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• A weekly summary of key developments in ECM and Event-Driven names that I track in Hong Kong, Australia, New Zealand, Singapore, Japan, Indonesia, Malaysia, Thailand, Korea, India, and Chinese ADRs.
• ECM developments: SHEIN Global Holdings (SHEIN HK) and GCash (Mynt) (GCASH PM) IPOs; Lintec Corp (7966 JP) secondary offering.
• Event-Driven developments: Baudroie (4413 JP), Ausgold Ltd (AUC AU), Carnaby Resources (CNB AU), EQT Holdings (EQT AU), European Lithium (EUR AU), Steadfast (SDF AU), Reliance Worldwide Corp (RWC AU). 

• HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for diseases promoted by chronic inflammation. It also commercializes proprietary compounds as reagents.
• HCW9302 showed preliminary clinical activity in Phase 1. HCW11-018b and HCW11-040 have Phase 1 trials planned for 2027. Founder Dr. Wong discovered Anktiva®.
• Material weaknesses were identified regarding long-lived assets and warrant modifications. Q1 2026 financial statements should not be relied upon due to an EPS calculation error.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.